Definium Therapeutics, Inc. DFTX
As ofNov 20, 2026, 3:00 PM EST
- YTD
- +114.56%
- 1 year
- +164.06%
5D -3.44 (-10.71%)
- Market cap
- 3.93B
- EPS (ttm)
- -2.92
- Shares out
- 136.90M
- Forward P/E
- -15.55
- YTD return
- +114.56%
- 1-year return
- +164.06%
- 50-day average
- 35.56
- 200-day average
- 30.61
- Enterprise value
- 2.98B
- Price / book
- 4.17
- Volume
- 2.36M
- Avg volume
- 1.98M
- Open
- 28.83
- Previous close
- 29.48
- Day's range
- 28.44 – 29.51
- 52-week range
- 10.47 – 49.70
- Beta
- 2.21
- Analysts
- Strong Buy
- Price target
- 72.83 (+153.5%)
- Earnings date
- Feb 25, 2027
Key statistics
- Free cash flow
- -118.64M
- Total cash
- 1.05B
- Total debt
- 36.66M
- Return on equity
- -61.44%
- Short % of float
- 7.07%
Fundamental scorecard
3 of 25 checks passed on DFTX’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 55.00
- Target (mean)
- 72.83
- Target (high)
- 91.00
- Strong buy5
- Buy14
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.48585.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.51 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.56294 | -0.46 | +0.10 | +18.29% |
| Aug 6, 2026 | Jun 30, 2026 | -0.54102 | -1.44 | -0.90 | -166.16% |
| May 7, 2026 | Mar 31, 2026 | -0.47 | -0.71 | -0.24 | -51.06% |
| Feb 26, 2026 | Dec 31, 2025 | -0.48368 | -0.51 | -0.03 | -5.44% |
| Nov 6, 2025 | Sep 30, 2025 | -0.52 | -0.78 | -0.26 | -50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 17, 2026 | JP Morgan | main | Overweight | Overweight |
| Nov 10, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 9, 2026 | JP Morgan | init | — | Overweight |
| Sep 15, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 15, 2026 | Baird | main | Outperform | Outperform |
| Sep 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- definiumtx.com
News
Your note
Sign in to keep a note on DFTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARROW ROBERT B | Chief Executive Officer | Sale | Sep 24, 2026 | 2,213,090 |
| BRUHN SUZANNE LOUISE | Director | Stock Award(Grant) | Jun 10, 2026 | 24,289 |
| CRYSTAL ROGER | Director | Stock Award(Grant) | Jun 10, 2026 | 24,289 |
| GRYSKA DAVID W | Director | Stock Award(Grant) | Jun 10, 2026 | 19,900 |
| KARLIN DANIEL ROLLINGS | Officer and Director | Sale | Sep 24, 2026 | 792,846 |
| KREBS ANDREAS | Director | Stock Award(Grant) | Jun 10, 2026 | 19,773 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.60% | 11,772,595 | 347.06M | Sep 29, 2026 |
| FMR, LLC | 6.63% | 9,082,203 | 267.74M | Sep 29, 2026 |
| Capital World Investors | 6.03% | 8,255,584 | 243.37M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 5.26% | 7,196,316 | 212.15M | Sep 29, 2026 |
| Avoro Capital Advisors LLC | 5.15% | 7,050,000 | 207.83M | Sep 29, 2026 |
| Driehaus Capital Management, LLC | 4.96% | 6,788,022 | 200.11M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 7.49% | 10,253,153 | 302.26M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.37% | 3,243,233 | 95.61M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.09% | 1,486,832 | 43.83M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.04% | 1,424,929 | 42.01M | Aug 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.94% | 1,287,318 | 37.95M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.86% | 1,170,713 | 34.51M | Sep 29, 2026 |
